MMR in the treatment of warts

A study in Egypt examined the efficacy and safety of using intralesional MMR vaccine to treat recalcitrant warts

Seventy men and women with multiple recalcitrant extragenital warts took part. Their largest wart was injected with 0.3 intralesional MMR vaccine every two weeks until clearance or until five injections had been given. Participants were followed up monthly for six months.

Of 65 patients completing the study, clearance was observed in 41 (63%), a partial response in 15 (23%) and no response in nine (14%). Only two patients experienced recurrence of the wart.

The researchers concluded that intralesional antigen immunotherapy using the MMR vaccine appears to be effective and safe and is therefore a promising treatment for patients with recalcitrant warts.

Nofal A, Nofal E, Yosef A et al. Int J Dermatol July 28 2014 doi: 10.1111/ijd.12480

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases